Home>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Demethylases>>NCGC00247743

NCGC00247743

Catalog No.GC32896

NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

NCGC00247743 Chemical Structure

Cas No.: 1435192-04-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$556.00
In stock
5mg
$506.00
In stock
10mg
$782.00
In stock
25mg
$1,471.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

Based on structure-activity relationship studies, a series of chemical compounds are derived from 8-hydroxyquinoline (8HQ) and shown to be active inhibitors of KDM4E and KDM4A. The effect of these compounds is tested on the growth of LNCaP cells and NCGC00247751 (A1), NCGC00244536 (B3), and NCGC00247743 (I9) are selected. These inhibitors inhibit LNCaP cell growth with IC50s in the μM range. These compounds also inhibit the enzymatic activity of other KDM4 isoforms although, interestingly, the potency and efficacy of B3 and A1 for KDM4A, 4C, and 4D are lower compared to that of NCGC00247743 (I9), suggesting a potential selectivity of the inhibitors for different isoforms of KDM4[1].

[1]. Duan L, et al. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. Chem Biol. 2015 Sep 17;22(9):1185-96.

Reviews

Review for NCGC00247743

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NCGC00247743

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.